List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1520016/publications.pdf Version: 2024-02-01

		31902	32761
123	10,324	53	100
papers	citations	h-index	g-index
127	127	127	8130
all docs	docs citations	times ranked	citing authors

RDIAN R FOLIN

#	Article	IF	CITATIONS
1	An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1992, 326, 1514-1521.	13.9	878
2	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genetics, 2013, 45, 164-171.	9.4	843
3	Intersecting Epidemics Crack Cocaine Use and HIV Infection among Inner-City Young Adults. New England Journal of Medicine, 1994, 331, 1422-1427.	13.9	539
4	Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013â€2016. Hepatology, 2019, 69, 1020-1031.	3.6	374
5	Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 2015, 62, 1353-1363.	3.6	364
6	Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet, The, 2001, 357, 1397-1401.	6.3	340
7	Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naÃ ⁻ ve patients. Hepatology, 2008, 48, 1769-1778.	3.6	326
8	High Prevalence of Abscesses and Cellulitis Among Community-Recruited Injection Drug Users in San Francisco. Clinical Infectious Diseases, 2000, 30, 579-581.	2.9	262
9	Risk Factors for Skin and Softâ€Tissue Abscesses among Injection Drug Users: A Caseâ€Control Study. Clinical Infectious Diseases, 2001, 33, 35-40.	2.9	226
10	Prevention of Peripheral Venous Catheter Complications With an Intravenous Therapy Team. Archives of Internal Medicine, 1998, 158, 473.	4.3	219
11	Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?. New England Journal of Medicine, 2001, 345, 211-214.	13.9	211
12	Naloxone Distribution and Cardiopulmonary Resuscitation Training for Injection Drug Users to Prevent Heroin Overdose Death: A Pilot Intervention Study. Journal of Urban Health, 2005, 82, 303-311.	1.8	197
13	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. Annals of Internal Medicine, 2013, 158, 235.	2.0	187
14	Overcoming Barriers to Prevention, Care, and Treatment of Hepatitis C in Illicit Drug Users. Clinical Infectious Diseases, 2005, 40, S276-S285.	2.9	185
15	Predictors and Prevention of Nonfatal Overdose Among Street-Recruited Injection Heroin Users in the San Francisco Bay Area, 1998–1999. American Journal of Public Health, 2001, 91, 1842-1846.	1.5	173
16	The effect of syringe exchange use on high-risk injection drug users: a cohort study. Aids, 2000, 14, 605-611.	1.0	172
17	USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: Disease-Specific Recommendations*. Clinical Infectious Diseases, 1995, 21, S32-S43.	2.9	167
18	Reinterpreting Ethnic Patterns among White and African American Men Who Inject Heroin: A Social Science of Medicine Approach. PLoS Medicine, 2006, 3, e452.	3.9	162

#	Article	IF	CITATIONS
19	Origins of Community Strains of Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases, 2004, 39, 47-54.	2.9	157
20	Tuberculosis in Patients Infected with Human Immunodeficiency Virus: Perspective on the Past Decade. Clinical Infectious Diseases, 1996, 22, 683-704.	2.9	153
21	Fatal Heroin-Related Overdose in San Francisco, 1997-2000: a Case for Targeted Intervention. Journal of Urban Health, 2003, 80, 261-273.	1.8	146
22	Spontaneous Clearance of Chronic Hepatitis C Virus Infection Is Associated With Appearance of Neutralizing Antibodies and Reversal of T-Cell Exhaustion. Journal of Infectious Diseases, 2012, 205, 763-771.	1.9	142
23	A Randomized Trial of Pegylated Interferon alpha-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C. American Journal of Gastroenterology, 2005, 100, 2453-2462.	0.2	127
24	A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug and Alcohol Dependence, 2003, 71, 127-131.	1.6	126
25	High-Risk Sex Behavior Among Young Street-Recruited Crack Cocaine Smokers in Three American Cities: An Interim Report. Journal of Psychoactive Drugs, 1992, 24, 363-371.	1.0	111
26	Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users. Clinical Infectious Diseases, 2004, 39, 1540-1543.	2.9	106
27	The High-Risk Sexual Practices of Crack-Smoking Sex Workers Recruited From the Streets of Three American Cities. Sexually Transmitted Diseases, 1998, 25, 187-193.	0.8	101
28	Transmission from One Child to Another of Human Immunodeficiency Virus Type 1 with a Zidovudine-Resistance Mutation. New England Journal of Medicine, 1993, 329, 1835-1841.	13.9	99
29	Individuals from North America, Australasia, and Africa Are Infected with Four Different Genotypes of Human Herpesvirus 8. Virology, 1999, 261, 106-119.	1.1	99
30	Risk factors among IDUs who give injections to or receive injections from other drug users. Addiction, 1999, 94, 675-683.	1.7	97
31	Crack Cocaine Use and Sexual Activity in Miami, Florida. Journal of Psychoactive Drugs, 1992, 24, 373-380.	1.0	96
32	Prevention and treatment of hepatitis C in injection drug users. Hepatology, 2002, 36, s210-s219.	3.6	94
33	Attitudes About Prescribing Take-Home Naloxone to Injection Drug Users for the Management of Heroin Overdose: a Survey of Street-Recruited Injectors in the San Francisco Bay Area. Journal of Urban Health, 2003, 80, 291-301.	1.8	94
34	Prevention and treatment of hepatitis C in injection drug users. Hepatology, 2002, 36, S210-S219.	3.6	92
35	Drug Paraphernalia Laws and Injection-Related Infectious Disease Risk among Drug Injectors. Journal of Drug Issues, 1999, 29, 1-16.	0.6	85
36	Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates. Journal of Clinical Microbiology, 2008, 46, 499-506.	1.8	85

#	Article	IF	CITATIONS
37	Sex-and Drug-Related Risk Among Populations of Younger and Older Injection Drug Users in Adjacent Neighborhoods in San Francisco. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 162-167.	0.9	82
38	Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. Journal of Infectious Diseases, 2014, 209, 350-354.	1.9	81
39	Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. Aids, 2003, 17, 215-222.	1.0	77
40	Human Immunodeficiency Virus Type 1 Superinfection Was Not Detected following 215 Years of Injection Drug User Exposure. Journal of Virology, 2004, 78, 94-103.	1.5	75
41	Crack Cocaine Smoking and Oral Sores in Three Inner-City Neighborhoods. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 87-92.	0.3	74
42	Use of an Illegal Syringe Exchange and Injection-Related Risk Behaviors Among Street-Recruited Injection Drug Users in Oakland, California, 1992 to 1995. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 505-511.	0.3	72
43	HIV Prevalence and Risk Behaviors Among Men Who Have Sex with Men and Inject Drugs in San Francisco. Journal of Urban Health, 2005, 82, i43-i50.	1.8	69
44	Perspective: Test and treat this silent killer. Nature, 2011, 474, s18-s19.	13.7	69
45	Sex-and Drug-Related Risk Among Populations of Younger and Older Injection Drug Users in Adjacent Neighborhoods in San Francisco. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 162-167.	0.9	67
46	Crack cocaine smokers who turn to drug injection: characteristics, factors associated with injection, and implications for HIV transmission. Drug and Alcohol Dependence, 1996, 42, 85-92.	1.6	65
47	Trends in Human Immunodeficiency Virus Seroincidence among Street-Recruited Injection Drug Users in San Francisco, 1987-1998. American Journal of Epidemiology, 2003, 157, 915-922.	1.6	65
48	Injection Drug Users: The Overlooked Core of the Hepatitis C Epidemic. Clinical Infectious Diseases, 2006, 42, 673-676.	2.9	62
49	Hepatitis C Virus (HCV)–Specific Immune Responses of Longâ€Term Injection Drug Users Frequently Exposed to HCV. Journal of Infectious Diseases, 2008, 198, 203-212.	1.9	62
50	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. Journal of Hepatology, 2015, 63, 1103-1110.	1.8	61
51	Legal aspects of providing naloxone to heroin users in the United States. International Journal of Drug Policy, 2001, 12, 237-248.	1.6	60
52	Evaluation of Infection Control Measures in Preventing the Nosocomial Transmission of Multidrug-Resistant Mycobacterium tuberculosis in a New York City Hospital. Infection Control and Hospital Epidemiology, 1995, 16, 141-147.	1.0	58
53	Urban rape survivors: Characteristics and prevalence of human immunodeficiency virus and other sexually transmitted infections. Obstetrics and Gynecology, 1995, 85, 330-336.	1.2	55
54	Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftrazidime plus amikacin for empiric treatment of febrile neutropenic patients. American Journal of Medicine, 1989, 87, S278-S282.	0.6	51

#	Article	IF	CITATIONS
55	Secondary Syringe Exchange Among Injection Drug Users. Journal of Urban Health, 2003, 80, 330-348.	1.8	51
56	Seroprevalence of Human Herpesvirus 8 among Injection Drug Users in San Francisco. Journal of Infectious Diseases, 2003, 187, 974-981.	1.9	51
57	Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology, 2007, 46, 666-671.	3.6	51
58	Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. Western Journal of Medicine, 2000, 172, 16-20.	0.3	51
59	Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PLoS ONE, 2017, 12, e0177341.	1.1	45
60	Trends in HIV Seroprevalence and Risk Among Gay and Bisexual Men Who Inject Drugs in San Francisco, 1988 to 2000. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 264-269.	0.9	43
61	Evaluation of Infection Control Measures in Preventing the Nosocomial Transmission of Multidrug-Resistant Mycobacterium tuberculosis in a New York City Hospital. Infection Control and Hospital Epidemiology, 1995, 16, 141-147.	1.0	43
62	Hepatitis C virusâ€specific Tâ€cell immune responses in seronegative injection drug users. Journal of Viral Hepatitis, 2009, 16, 10-20.	1.0	41
63	Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program. Open Forum Infectious Diseases, 2018, 5, ofy048.	0.4	41
64	Community Characteristics Associated with HIV Risk among Injection Drug Users in the San Francisco Bay Area: A Multilevel Analysis. Journal of Urban Health, 2007, 84, 653-666.	1.8	40
65	Use of Health Care Services by Women Who Use Crack Cocaine. Women and Health, 2000, 30, 35-51.	0.4	38
66	Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infectious Diseases, The, 2016, 16, e196-e201.	4.6	37
67	In-Vitro Resistance to Zidovudine and Alpha-interferon in HIV-1 Isolates from Patients: Correlations with Treatment Duration and Response. Annals of Internal Medicine, 1992, 117, 457-460.	2.0	36
68	What's Community Got to Do With It? Implementation Models of Syringe Exchange Programs. AIDS Education and Prevention, 2005, 17, 68-78.	0.6	36
69	Can hepatitis C be eradicated in the United States?. Antiviral Research, 2014, 110, 79-93.	1.9	35
70	Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. Journal of Hepatology, 2011, 55, 545-553.	1.8	34
71	Sex Trading and Psychological Distress in a Street-Based Sample of Low-Income Urban Men. Journal of Psychoactive Drugs, 2000, 32, 259-267.	1.0	32
72	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology, 2019, 156, 1496-1507.e7.	0.6	32

#	Article	IF	CITATIONS
73	Human Immunodeficiency Virus and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010–2017. Journal of Infectious Diseases, 2020, 222, 940-947.	1.9	31
74	Incentives and accessibility: A pilot study to promote adherence to TB prophylaxis in a high-risk community. Journal of Urban Health, 1999, 76, 461-467.	1.8	29
75	Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. International Journal of Drug Policy, 2004, 15, 81-91.	1.6	27
76	HCV RNA levels in a multiethnic cohort of injection drug users: Human genetic, viral and demographic associations. Hepatology, 2012, 56, 86-94.	3.6	25
77	Accessible Hepatitis C Care for People Who Inject Drugs. JAMA Internal Medicine, 2022, 182, 494.	2.6	25
78	Hepatitis D Viremia Among Injection Drug Users in San Francisco. Journal of Infectious Diseases, 2018, 217, 1902-1906.	1.9	24
79	Genetic variation in <i>CLDN1</i> and susceptibility to hepatitis C virus infection. Journal of Viral Hepatitis, 2010, 17, 192-200.	1.0	22
80	IL28B rs12979860 Genotype and Spontaneous Clearance of Hepatitis C Virus in a Multi-Ethnic Cohort of Injection Drug Users: Evidence for a Supra-Additive Association. Journal of Infectious Diseases, 2011, 204, 1843-1847.	1.9	21
81	Intrahepatic CD4+ Cell Depletion in Hepatitis C Virus/HIV???Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1125-1131.	0.9	20
82	Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infectious Diseases, 2007, 7, 145.	1.3	20
83	Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infectious Diseases, 2011, 11, 208.	1.3	19
84	The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. Journal of Viral Hepatitis, 2008, 15, 690-698.	1.0	17
85	Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum αâ€fetoprotein. Liver International, 2004, 24, 198-203.	1.9	16
86	More Rare Birds, and the Occasional Swan. Gastroenterology, 2009, 136, 2412-2414.	0.6	15
87	Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations. Value in Health, 2017, 20, 736-744.	0.1	15
88	HIV/Hepatitis C Virus-Coinfected Patients With Normal Alanine Aminotransferase Levels. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 582-589.	0.9	14
89	Prescription opioid injection among young people who inject drugs in New York City: a mixed-methods description and associations with hepatitis C virus infection and overdose. Harm Reduction Journal, 2020, 17, 22.	1.3	14
90	Racial/Ethnic Differences in Spontaneous HCV Clearance in HIV Infected and Uninfected Women. Digestive Diseases and Sciences, 2013, 58, 1341-1348.	1.1	13

#	Article	IF	CITATIONS
91	A Comparison of Process and Outcome at Two Hospitals. Chest, 1997, 112, 398-405.	0.4	12
92	The Risk of Emergency Room Treatment Due to Overdose in Injection Drug Users. Journal of Addictive Diseases, 2009, 28, 68-73.	0.8	12
93	Pandemic Influenza: Implications for Programs Controlling for HIV Infection, Tuberculosis, and Chronic Viral Hepatitis. American Journal of Public Health, 2009, 99, S333-S339.	1.5	12
94	Managing hepatitis C in users of illicit drugs. Current Hepatitis Reports, 2007, 6, 60-67.	0.3	11
95	Hepatitis C screening: Getting it right. Hepatology, 2013, 57, 1644-1650.	3.6	11
96	Harm reduction and needle exchange programmes. Lancet, The, 1998, 351, 1819-1820.	6.3	10
97	Prevalence of SEN Viruses among Injection Drug Users in the San Francisco Bay Area. Journal of Infectious Diseases, 2003, 188, 13-18.	1.9	10
98	MBL2and Hepatitis C Virus Infection among Injection Drug Users. BMC Infectious Diseases, 2008, 8, 57.	1.3	9
99	The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury—The Women's Interagency HIV Study. PLoS ONE, 2017, 12, e0181004.	1.1	9
100	Tuberculin Skin Testing of Hospital Employees During an Outbreak of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus (HIV) -Infected Patients. Infection Control and Hospital Epidemiology, 1992, 13, 509-510.	1.0	8
101	Persistent HIV Incidence Among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1667-1669.	0.9	7
102	Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. Vaccine, 2016, 34, 1363-1369.	1.7	7
103	Tuberculin Skin Testing of Hospital Employees during an Outbreak of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus (HIV)-Infected Patients. Infection Control and Hospital Epidemiology, 1992, 13, 509-510.	1.0	6
104	Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. PLoS ONE, 2015, 10, e0138827.	1.1	6
105	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Scientific Reports, 2017, 7, 15843.	1.6	6
106	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQI21. American Journal of Human Genetics, 2022, 109, 299-310.	2.6	6
107	Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet, The, 1993, 341, 570-571.	6.3	5
108	Crack Cocaine and HIV in the Inner City. New England Journal of Medicine, 1995, 332, 1233-1235.	13.9	5

#	Article	IF	CITATIONS
109	HCV infection clearance with functional or non-functional caspase-12. Scandinavian Journal of Gastroenterology, 2007, 42, 416-417.	0.6	5
110	Hepatitis C virus (HCV) <scp>RNA</scp> profiles among chronic HIV/HCV oinfected individuals in <scp>ESPRIT</scp> ; spontaneous HCV <scp>RNA</scp> clearance observed in nine individuals. HIV Medicine, 2017, 18, 430-434.	1.0	5
111	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Journal of Infectious Diseases, 2021, 223, 2090-2098.	1.9	5
112	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes and Immunity, 2020, 21, 348-359.	2.2	5
113	Evaluation of Infection Control Measures in Preventing the Nosocomial Transmission of Multidrug-Resistant Mycobacterium tuberculosis in a New York City Hospital. Infection Control and Hospital Epidemiology, 1995, 16, 141-147.	1.0	1
114	Change of HAART. Lancet, The, 1999, 353, 1888.	6.3	1
115	PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. Journal of Medical Virology, 2004, 73, 123-130.	2.5	1
116	Reply:. Hepatology, 2019, 70, 759-760.	3.6	1
117	Clusters of Multidrug-Resistant Tuberculosis. Annals of Internal Medicine, 1993, 118, 77.	2.0	1
118	Trends in HIV Seroprevalence and Risk Among Gay and Bisexual Men Who Inject Drugs in San Francisco, 1988 to 2000. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 264-269.	0.9	0
119	Written in Response to Scott LD: Treating Hepatitis C in Active Injection Drug Users. American Journal of Gastroenterology, 2005, 100, 2131-2132.	0.2	0
120	S2085 Non-Invasive Hepatic Fibrosis Assay Scores Increase with Increasing Age in Patients with Chronic Hepatitis C. Gastroenterology, 2009, 136, A-327.	0.6	0
121	Cocaine-Levamisole Thrombovasculopathy: A Report From the Southern Network On Adverse Reactions (SONAR) Project. Blood, 2012, 120, 3403-3403.	0.6	0
122	Preventing perinatal HIV transmission. JAMA - Journal of the American Medical Association, 1996, 276, 779-780.	3.8	0
123	Transforming strategies to provide access to care. Journal of Family Practice, 2010, 59, S59-64.	0.2	О